FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
Is Guardant Health winning the race towards MCED?
Those following the field of Multi-Cancer Early Detection (MCED) might have caught this in the news, what could be an important win for Guardant Health GH 0.00%↑ in the race for MCED. The stock reacted very positively to the news, and it’s up +16% in the 5-day window span.
Some of their competitors, such as Exact Sciences EXAS 0.00%↑ , Tempus AI TEM 0.00%↑ , or Grail Bio GRAL 0.00%↑ are either…